The main purposes of this study are to determine:
- The safety of LY3502970 and any side effects that might be associated with it.
- How much LY3502970 gets into the bloodstream and how long it takes the body to get rid
of it.
This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970
and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last
about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days.
Each participant will enroll in only one part. Screening must be completed within 28 days
before study start. This study is for research purposes only, and is not intended to treat
any medical condition.